Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model

Nephrology Dialysis Transplantation

Volumn 23, Issue 5, 2008, Pages 1521-1528

  Kitamura, Harumi ^a   Isaka, Yoshitaka ^a   Takabatake, Yoshitsugu ^a   Imamura, Ryoichi ^a   Suzuki, Chigure ^a   Takahara, Shiro ^a   Imai, Enyu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Carbamylated erythropoietin; Tubulointerstitial injury; Ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARBAMOYLATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; KIDNEY INFARCTION; KIDNEY INTERSTITIUM; KIDNEY TUBULE DAMAGE; LOW DRUG DOSE; MALE; NONHUMAN; POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; TUBULOINTERSTITIAL INJURY; URETER OBSTRUCTION;

ACTINS; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMOGLOBINS; INFARCTION; KIDNEY; KIDNEY TUBULES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION; URETERAL OBSTRUCTION;

EID: 44449166538     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm842     Document Type: Article

References (32)

1. Nath KA. Am J Kidney Dis 1992; 20: 1-17
2. Phillips AO, Steadman R. Histol Histopathol 2002; 17: 247-252
3. Uchiyama-Tanaka Y, Mori Y, Kimura T et al. Am J Kidney Dis 2004; 43: e18-e25
4. Eddy AA. J Am Soc Nephrol 1996; 7: 2495-2508
5. Klahr S, Morrissey J. Am J Physiol Renal Physiol 2002; 283: F861-F875
6. Klahr S, Schreiner G, Ichikawa I. N Engl J Med 1988; 318: 1657-1666
7. Sharma AK, Mauer SM, Kim Y et al. Kidney Int 1993; 44: 774-788
8. Sakanaka M, Wen TC, Matsuda S et al. Proc Natl Acad Sci USA 1998; 95: 4635-4640
9. Siren AL, Fratelli M, Brines M et al. Proc Natl Acad Sci USA 2001; 98: 4044-4049
10. Nangaku M. J Am Soc Nephrol 2006; 17: 17-25
11. Kuriyama S, Tomonari H, Yoshida H et al. Nephron 1997; 77: 176-185
12. Garcia DL, Anderson S, Rennke HG et al. Proc Natl Acad Sci USA 1988; 85: 6142-6146
13. Westenfelder C, Biddle DL, Baranowski RL. Kidney Int 1999; 55: 808-820
14. Henke M, Laszig R, Rube C et al. Lancet 2003; 362: 1255-1260
15. Phrommintikul A, Haas SJ, Elsik M et al. Lancet 2007; 369: 381-388
16. Drueke TB, Locatelli F, Clyne N et al. N Engl J Med 2006; 355: 2071-2084
17. Singh AK, Szczech L, Tang KL et al. N Engl J Med 2006; 355: 2085-2098
18. Brines M, Grasso G, Fiordaliso F et al. Proc Natl Acad Sci USA 2004; 101: 14907-14912
19. Leist M, Ghezzi P, Grasso G et al. Science 2004; 305: 239-242
20. Savino C, Pedotti R, Baggi F et al. J Neuroimmunol 2006; 172: 27-37
21. Truong LD, Petrusevska G, Yang G et al. Kidney Int 1996; 50: 200-207
22. Imamura R, Isaka Y, Ichimaru N et al. Biochem Biophys Res Commun 2007; 353: 786-792
23. Cantley LC. Science 2002; 296: 1655-1657
24. Kashii Y, Uchida M, Kirito K et al. Blood 2000; 96: 941-949
25. Chavakis T, Kanse SM, Lupu F et al. Blood 2000; 96: 514-522
26. Silva M, Grillot D, Benito A et al. Blood 1996; 88: 1576-1582
27. Henke M, Mattern D, Pepe M et al. J Clin Oncol 2006; 24: 4708-4713
28. Wright JR, Ung YC, Julian JA et al. J Clin Oncol 2007; 25: 1027-1032
29. Stohlawetz PJ, Dzirlo L, Hergovich N et al. Blood 2000; 95: 2983-2989
30. Wolf RF, Peng J, Friese P et al. Thromb Haemost 1997; 78: 1505-1509
31. Brines M, Cerami A. Kidney Int 2006; 70: 246-250
32. Peterson L. FDA oncologic drugs advisory committee (ODAC) meeting on the safety of erythropoietin in oncology. Trends Med 2004; 1-4